Literature DB >> 33761470

Fractional-order model representations of apparent vascular compliance as an alternative in the analysis of arterial stiffness: anin-silicostudy.

Mohamed A Bahloul1, Taous-Meriem Laleg Kirati1.   

Abstract

Objective. Recent studies have demonstrated the advantages of fractional-order calculus tools for probing the viscoelastic properties of collagenous tissue, characterizing the arterial blood flow and red cell membrane mechanics, and modeling the aortic valve cusp. In this article, we present novel lumped-parameter equivalent circuit models for apparent arterial compliance using a fractional-order capacitor (FOC). FOCs, which generalize capacitors and resistors, display a fractional-order behavior that can capture both elastic and viscous properties through a power-law formulation.Approach. The proposed framework describes the dynamic relationship between the blood-pressure input and the blood volume, using linear fractional-order differential equations.Main results. The results show that the proposed models present a reasonable fit with thein-silicodata of more than 4000 subjects. Additionally, strong correlations have been identified between the fractional-order parameter estimates and the central hemodynamic determinants as well as the pulse-wave velocity indexes.Significance. Therefore, the fractional-order-based paradigm for arterial compliance shows notable potential as an alternative tool in the analysis of arterial stiffness. Creative Commons Attribution license.

Keywords:  Apparent compliance; Arterial stiffness; Cardiovascular system; Fractional order capacitor; Input Impedance; fractional calculus

Year:  2021        PMID: 33761470     DOI: 10.1088/1361-6579/abf1b1

Source DB:  PubMed          Journal:  Physiol Meas        ISSN: 0967-3334            Impact factor:   2.833


  1 in total

1.  Human Hypertension Blood Flow Model Using Fractional Calculus.

Authors:  Mohamed A Bahloul; Yasser Aboelkassem; Taous-Meriem Laleg-Kirati
Journal:  Front Physiol       Date:  2022-03-22       Impact factor: 4.566

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.